# A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma

> **NCT03153085** · PHASE2 · COMPLETED · sponsor: **Takara Bio Inc.** · enrollment: 28 (actual)

## Conditions studied

- Melanoma Stage III
- Melanoma Stage IV

## Interventions

- **BIOLOGICAL:** TBI-1401(HF10)
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03153085
- **Lead sponsor:** Takara Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-25
- **Primary completion:** 2018-06-30
- **Final completion:** 2018-12-14
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03153085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03153085, "A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03153085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*